Clinical trial NCT07025824: Randomized Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Official title: Randomized Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: AML - Acute Myeloid Leukemia
MDS (Myelodysplastic Syndrome)
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
Collaborators: name: medac GmbH
First posted: 2025-06-18
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation.

The following will also be investigated:

* Survival
* Remission and Relapse rate
* Engraftment or graft failure
* Graft versus Host Disease (GvHD)


Eligibility criteria: Main Inclusion Criteria:

1. Informed consent signed by the patient capable of giving
2. Patient scheduled for allogeneic transplantation within the next 3 weeks
3. Age ≥ 18 years
4. AML or MDS according to WHO with indication for allogeneic HCT:

   1. AML in first or second complete remission (CR) or complete remission with incomplete hematologic recovery (CRi/CRh) or morphologic leukemia-free state (MLFS)
   2. MDS according to WHO
5. Increased risk for treatment-related toxicity by myeloablative conditioning according to at least one of the following criteria:

   1. Patients aged ≥ 50 years at transplant and/or
   2. HCT-CI \> 2 and/or
   3. AML or MDS scheduled for 2nd allogeneic HCT from different donor with minimum of 12 months after 1st allogeneic HCT
6. Availability of a suitable donor:

   1. Matched sibling donor (MSD) or
   2. matched unrelated donor (MUD, 10/10 HLA) or
   3. mismatched unrelated donor (MMUD, single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent -DQB1 mismatch (9/10) shown by confirmatory typing) or
   4. haploidentical family donor
7. Planned GvHD prophylaxis with standard PTCy (with 50mg/kg body weight on days +3 and +4)
8. No history of cardiac disease that preclude allogeneic HCT and absence of active symptoms, otherwise, documented left ventricular ejection fraction

   * 40 %.
9. No need for supplementary oxygen on day of randomization

Main Exclusion Criteria:

1. Patients with acute promyelocytic leukemia with t(15;17)(q22;q12)
2. Patients with graft failure after previous allogeneic HCT
3. Patients with scheduled 2nd allogeneic HCT within 12 months after 1st allogeneic HCT
4. Pretreatment with either melphalan or treosulfan within the last 12 months prior to randomization
5. Planned TBI as part of conditioning
6. Severe organ dysfunction defined by either one of the following criteria:

   1. Serum bilirubin \> 1.5 × ULN (if not considered Gilbert-syndrome) or
   2. ALAT or ASAT \> 5 × ULN
7. Uncontrolled infection at the time of randomization.
8. Active viral hepatitis unless serology demonstrates clearance of infection. Occult or prior hepatitis B virus (HBV) infection, defined as negative hepatitis B surface antigen and positive total hepatitis core antibodies, may be included if HBV DNA is undetectable, provided that patients are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior cured hepatitis B are eligible. Patients for hepatitis C virus (HCV) antibody are eligible provided PCR if negative for HCV RNA.
9. Pregnant or breastfeeding women

Primary outcomes:
measure: overall survival (OS)
timeFrame: 2 years after randomization
Secondary outcomes:
measure: non-relapsed mortality (NRM)
timeFrame: 2 years after randomization
measure: relapse-free survival (RFS)
timeFrame: 2 years after randomization
measure: -Cumulative incidences of acute and chronic GvHD
timeFrame: 2 years after randomization
measure: Rates of AEs/SAEs/AESI
timeFrame: 56 days after allogeneic stem cell transplantation
measure: -Cumulative incidence of relapse (CIR)
timeFrame: 2 years after randomization
measure: -Rate of engraftment on day +28
timeFrame: 2 years after randomization
measure: Rate of morphologic and molecular CR/CRh/CRi/MLFS
timeFrame: day +56 after allogeneic stem cell transplantation
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I
city: Halle (Saale)
country: Germany
facility: Universitätsmedizin Halle (Saale)
city: Kiel
country: Germany
facility: Universitätsklinikum Schleswig-Holstein, Campus Kiel
city: Münster
country: Germany
facility: Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum
Study officials:
References: